Senseonics Holdings, which is developing a long-lasting implantable glucose monitor for diabetics, raised $45 million by offering 15.8 million shares at $2.85. Senseonics Holdings plans to list on the NYSE MKT under the symbol SENS. Leerink Partners and Canaccord Genuity acted as lead managers on the deal.
